A Dutch/German public-private consortium of PamGene, GenXpro and the University Medical Center Groningen has been awarded a research grant from the EU Eurostars-2 program for the Triple T project of €1.55 million: Rationalized Tailored Targeted Therapy for Cancer.
The project Triple T was initiated through Vivomicx BV, a spin off from the University Medical Center Groningen. The 36 month joint research project is expected to deliver a series of optimized and validated miniaturized technologies for tumor sample analysis that will be established as a service to doctors treating patients with lung cancer.
This first service of its kind in the field of lung cancer will enable clinicians to precisely tailor treatments to their individual patient’s needs.
For more details, download the Press Release here: